A promising new medicine against heart disease fails unexpectedly
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"A promising new medicine against heart disease fails unexpectedly" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 10d ago.
Quick answers
Why is "A promising new medicine against heart disease fails unexpectedly" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing Reuters · 10d ago
- Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs Fierce Biotech · 10d ago
Topics
Related trends
Nike hosts first investor day in 9 years as it tries to rightsize its business
Nike holds its first investor day since 2017, unveiling a 2031 financial framework and Full Stride Ahead strategy to reverse declining sales.
Disney beats fourth-quarter estimates, targets $3 billion in savings through cost-cutting efforts
Disney beat Q4 earnings estimates with $1.77 adjusted EPS on $25.9B revenue and announced a $3B cost-savings target by 2029 alongside a 33% dividend increase.
Diamondback nears $5 billion deal to buy drilling portfolio from Double Eagle, FT says
Diamondback Energy agreed to buy Double Eagle subsidiaries for about 15.56 million shares and $2.15 billion cash, valuing the deal at roughly $5 billion, with closing expected December 21, 2026.
Gen Z judges colleagues who use AI, but paradoxically may see it as the key to their own promotion
New survey coverage reveals a stark generational paradox as younger workers harbor deep concerns over artificial intelligence while eyeing promotion pathways.
Nvidia bought itself a little breathing room in the Jensen Huang comeback fight
Nvidia secures vital breathing room amid the ongoing Jensen Huang comeback battle according to Business Insider.
Morning Bid: Jensen Huang's last hurrah, and a nervy future for Nvidia
An Indian Nvidia employee publicly praises Jensen Huang for past support during a difficult time.